Priothera closes 30m Series A financing
Priothera Ltd. wants to use 30m from a Series A financing to develop a licenced therapy for acute myeloid leukemia (AML).
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1335 entries already.
Entries by Thomas Gabrielczyk
COVID-19 jab: EU signs contract with JNJ
/in News/by Thomas GabrielczykJohnson & Johnson (JNJ) has inked a contract with the European Commission to supply 200 million doses of its COVID-19 vaccine to the European Union.
Santhera ends development of idebenone
/in News/by Thomas GabrielczykSwiss Santhera Pharmaceuticals has discontinued Phase III development of its DMD drug and will restructure its pipeline.
Nobel Prize in Physiology for HCV pioneers
/in News/by Thomas GabrielczykThe Nobel Prize in Physiology or Medicine goes to Harvey J. Alter, Michael Houghton and Charles M. Ric
Swiss Sophia Genetics to expand globally
/in News/by Thomas GabrielczykSwiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally.
EIB and EC launch circular bioeconomy fund
/in News/by Thomas GabrielczykThe European Commission (EC) and the European Investment Bank (EIB) have launched a circular bioeconomy fund with a target size of 250m. ·
Dewpoint Therapeutics raise $77m in Series B financing
/in News/by Thomas GabrielczykA $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
Kurma Partners close diagnostics fund at 50m
/in News/by Thomas GabrielczykThe only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at 50m.
Danish Galecto Inc. secures US$64m equity financing
/in News/by Thomas GabrielczykDanish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
MosaMeat NV bags US$55m financing
/in News/by Thomas GabrielczykMaastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.